Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
相关临床试验
3
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2018
进行中（未招募）
3
100.0%
暂无批准数据
- Sana Biotechnology (NASDAQ:SANA) received an upgrade from "sell" to "hold" by Wall Street Zen, while maintaining a consensus "Moderate Buy" rating with an average price target of $9.50. - The company reported Q1 earnings of ($0.14) per share, beating consensus estimates by $0.01, with analysts projecting full-year EPS of ($0.59). - Sana Biotechnology is a clinical-stage biopharma developing engineered cell therapies using gene editing tools including CRISPR–Cas9 for oncology and genetic disorders. - The stock experienced an 11.1% decline on Thursday, trading at $3.16, with a market capitalization of approximately $880 million and institutional ownership at 88.23%.
- Sana Biotechnology is advancing a dual-platform cell engineering strategy encompassing both ex vivo and in vivo approaches to create medicines for diseases with significant unmet need. - The company's oncology pipeline targets CD19+ cancers including non-Hodgkin lymphoma, CLL, and ALL, as well as multiple myeloma, with programs such as SG295, SC291, and SG221. - Beyond oncology, Sana is developing candidates for genetic disorders (SG328 for OTC deficiency), blood disorders (SG418 for sickle cell disease), type 1 diabetes (SC451), and CNS disorders including Huntington's disease (SC379). - Led by co-founder and CEO Steve Harr, formerly of Juno Therapeutics, the company remains in the preclinical/developmental stage with no approved or commercialized products.
- Halper Sadeh LLC is investigating whether Sana Biotechnology officers and directors breached their fiduciary duties to shareholders. - The law firm is encouraging long-term shareholders to contact them regarding potential corporate governance reforms and financial relief. - Shareholders may be able to seek the return of funds to the company, court-approved financial incentives, or other benefits through legal action. - The investigation highlights potential corporate governance issues at the biotechnology company that could impact shareholder value.
- Sana Biotechnology will present preclinical data on SG293, a CD19-directed in vivo CAR-T product candidate, at the ASGCT 2026 Annual Meeting in Boston. - SG293 uses proprietary fusogen-based delivery technology to specifically target CD8+ T cells while avoiding off-target delivery to organs like the liver. - The therapy represents a differentiated approach for both oncology and autoimmune indications, potentially addressing key safety concerns with current CAR-T therapies. - The oral presentation titled "Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293" will be delivered on May 12, 2026.
- Flagship Pioneering and Amazon Web Services announced a strategic collaboration to accelerate breakthrough life sciences companies through cloud computing and AI capabilities. - Early-stage Flagship companies will receive AWS cloud credits, technical support, and AI services to build digitally native platforms across human health and sustainability domains. - The partnership aims to transform drug discovery processes by providing scalable infrastructure that enables rapid experimentation and seamless transition from discovery to deployment. - AWS will serve as the preferred cloud provider for Flagship's portfolio, which includes over 40 companies such as Moderna and operates with $14 billion in assets under direction.
- Sana Biotechnology has appointed Brian Piper as Executive Vice President and Chief Financial Officer, bringing over 25 years of biopharmaceutical financial expertise to the engineered cell therapy company. - The company expects to generate initial clinical data for SC451 in type 1 diabetes treatment and SG293 in B-cell related diseases within the next 12-18 months. - Piper previously served as CFO at Scorpion Therapeutics until its acquisition by Eli Lilly in 2025, and brings experience in capital formation and operational excellence. - The appointment comes at a pivotal time as Sana advances its hypoimmune-modified pancreatic islet cell therapy and in vivo CAR-T platform programs.
- Sana Biotechnology published breakthrough research in Nature Biotechnology demonstrating potent in vivo gene editing of hematopoietic stem cells in bone marrow using their fusogen technology platform. - The virus-like particle delivery system achieved cell-specific targeting of HSCs while avoiding off-target delivery to hepatocytes, potentially eliminating the need for conditioning chemotherapy. - This advancement broadens fusogen technology applications beyond T cells to HSCs, with potential to transform treatment of sickle cell disease and beta thalassemia. - The company plans to file an IND for SG293, a CD19-directed CAR T cell therapy, for B-cell cancers and autoimmune diseases as early as 2027.
- Sana Biotechnology has strategically pivoted to concentrate resources on two flagship programs: SC451 for Type 1 diabetes and the in-vivo CAR-T platform SG293, while suspending funding for allogeneic CAR-T studies SC291 and SC262. - The company's SC451 diabetes program is supported by encouraging early clinical data published in the New England Journal of Medicine, demonstrating safety and insulin production capability without immunosuppression. - Sana reported improved third-quarter 2025 financials with a narrowed net loss of $42.2 million and maintains $170.5 million in pro-forma liquidity, sufficient to fund operations into the latter half of 2026. - An Investigational New Drug (IND) application for SC451 could be filed as early as 2026, with SG293 targeting B-cell cancers or autoimmune diseases anticipated for IND submission in 2027.
- King Abdullah International Medical Research Center and Flagship Pioneering announced a strategic partnership to conduct early-phase clinical trials of novel genetic disease therapies in Saudi Arabia. - The collaboration will initially focus on three Phase 1 programs and one Phase 2 program from Flagship-founded companies targeting genetic diseases with high unmet medical need. - Saudi investors will commit $70 million to participating U.S.-based companies as part of the partnership framework. - The agreement aims to establish Saudi Arabia as a leader in innovative clinical trials while advancing American biotechnology innovation globally.
- CAMP4 Therapeutics announced an oversubscribed $100 million private placement led by Coastlands Capital to fund development of its first-in-class SYNGAP1 treatment program. - The financing provides $50 million upfront with potential for additional $50 million upon achieving regulatory milestones, including clearance for Phase 1/2 clinical trials expected to begin in 2H 2026. - The company appointed Doug Williams as Board Chair and elevated Daniel Tardiff to Chief Scientific Officer to strengthen leadership as it advances its regulatory RNA-targeting therapeutic platform. - CAMP4's approach targets regulatory RNAs to upregulate gene expression and restore healthy protein levels in genetic diseases, addressing over 1,200 haploinsufficient disorders.
